GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scancell Holdings PLC (FRA:SCP) » Definitions » Capex-to-Operating-Income

Scancell Holdings (FRA:SCP) Capex-to-Operating-Income : 0.00 (As of Oct. 2023)


View and export this data going back to 2013. Start your Free Trial

What is Scancell Holdings Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Scancell Holdings's Capital Expenditure for the six months ended in Oct. 2023 was €-0.02 Mil. Its Operating Income for the six months ended in Oct. 2023 was €-9.37 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.


Scancell Holdings Capex-to-Operating-Income Historical Data

The historical data trend for Scancell Holdings's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scancell Holdings Capex-to-Operating-Income Chart

Scancell Holdings Annual Data
Trend Apr14 Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23
Capex-to-Operating-Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Scancell Holdings Semi-Annual Data
Apr14 Oct14 Apr15 Oct15 Apr16 Oct16 Apr17 Oct17 Apr18 Oct18 Apr19 Oct19 Apr20 Oct20 Apr21 Oct21 Apr22 Oct22 Apr23 Oct23
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Scancell Holdings's Capex-to-Operating-Income

For the Biotechnology subindustry, Scancell Holdings's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Scancell Holdings's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Scancell Holdings's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Scancell Holdings's Capex-to-Operating-Income falls into.



Scancell Holdings Capex-to-Operating-Income Calculation

Scancell Holdings's Capex-to-Operating-Income for the fiscal year that ended in Apr. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-0.231) / -13.538
=N/A

Scancell Holdings's Capex-to-Operating-Income for the quarter that ended in Oct. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-0.015) / -9.366
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Scancell Holdings  (FRA:SCP) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Scancell Holdings Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Scancell Holdings's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Scancell Holdings (FRA:SCP) Business Description

Traded in Other Exchanges
Address
Sanders Road, Unit 202, Bellhouse Building, Oxford Science Park, Oxford, GBR, OX4 4GD
Scancell Holdings PLC is engaged in the discovery and development of novel vaccines for the treatment of cancer. The company is exploiting the unrivalled potential of the immune system to seek out and destroy cancer using two proprietary immuno-oncology platforms: ImmunoBody and Moditope. Its potent innovative DNA-based ImmunoBody therapies generate ultra-high avidity T cell responses that target and eliminate cancerous tumors. Its Moditope platform technology overcomes the immune suppression induced by tumors themselves, allowing activated T cells to seek out and kill tumor cells that would otherwise be hidden from the immune system.

Scancell Holdings (FRA:SCP) Headlines

No Headlines